European Orphan Drug Designation (“ODD”) qualifies NXC-201 for:
10 years of market exclusivity once authorized in the EU
Access to the EU centralized authorization procedure
Reduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees
April 29, 2024 -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-sta